Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
|27/04/2018||Appendix 3Y-Bill Garner||Download|
|20/04/2018||Appendix 4C - quarterly||Download|
|11/04/2018||Race signs global distribution agreement with Durbin PLC||Download|
|06/04/2018||Initial Director's Interest Notice||Download|
|04/04/2018||Final Director's Interest Notice||Download|
|04/04/2018||Race appoints former Sanofi executive to the Board||Download|
|20/03/2018||Change in substantial holding||Download|